

# “Severe Anemia: A Case Report of an Uncommon Precipitant of Schizophrenia Relapse”

Krittisak Anuroj , Siwat Chongbanyatcharoen, Romteera Chiencharoenthanakij

Department of Psychiatry, Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok, Thailand

Correspondence: Krittisak Anuroj, Department of Psychiatry, Faculty of Medicine, Srinakharinwirot University, 62 Moo 7 Ongkharak Subdistrict, Ongkharak District, Nakhon Nayok, 26120, Thailand, Tel +6637385085 Ext. 60804, Email thymelancille@gmail.com

**Abstract:** A 48-year-old patient with stable residual schizophrenia experienced a syndromic psychosis relapse following an episode of severe combined immunohemolytic and pure red cell aplastic anemia, with a hemoglobin level of 4.7 g/dl. The anemia was attributed to her anti-HIV medication zidovudine. Her HIV infection had been well-controlled; no other organic precipitant of the psychosis was found. Following transfusion of 2 units of leukocyte-poor packed red cells, schizophrenia symptoms promptly recovered to her baseline. This was maintained at 3- and 6-month follow-ups without any need for antipsychotic dose adjustment. Following zidovudine discontinuation and a short course of oral prednisolone, her anemia gradually recovered.

**Keywords:** neuropsychiatric, psychiatric, hematologic, zidovudine, HIV infection

## Plain Language Summary

The authors describe a case of stable schizophrenia that had a relapse due to severe anemia. Blood transfusion resulted in quick and complete recovery to the patient's baseline.

## Introduction

A recent estimate projected that anemia affects 26.8% of the population worldwide and is associated with 58.6 million years lived with disability, making it a public health concern. The signs and symptoms of anemia vary by severity, onset and chronicity, and etiology of the condition. End-organ symptoms from poor perfusion can be present in those with chronic or progressive anemia, causing symptoms such as fatigue, decrease in stamina, light-headedness, dyspnea, exercise intolerance, or syncope.<sup>1</sup> Affecting the brain, anemia can manifest with neuropsychiatric presentations including mood disorders, anxiety disorders, and psychoses.<sup>2-6</sup> Vitamin B12 deficiency, a cause of megaloblastic anemia, is known to cause psychosis regardless of the presence of anemia,<sup>7-9</sup> through mechanisms related to one-carbon metabolisms and syntheses of neurotransmitters.<sup>10,11</sup> Iron deficiency, another common entity, can affect dopamine receptor levels and disrupt functions of sensitive brain regions resulting in psychosis, again regardless of presence of anemia.<sup>12,13</sup>

Schizophrenia is a debilitating psychiatric disease with core symptoms of delusion and hallucination, affecting approximately 1% of the world's population.<sup>14</sup> At its onset, schizophrenia itself has been associated with low serum iron level, but not with anemia.<sup>12,15</sup> However, data on association between schizophrenia relapse and anemia are scarce. A PubMed search performed on 23 October 2022 with search string “(anemia OR anemic) AND (schizophrenia OR schizophrenic OR schizophreniform)” yielded 194 results, among which only one article was relevant: a case report of a known schizophrenia patient with multiple comorbidities presenting with hallucination from sickle cell crisis in 1991. The case passed away during the admission, hence there were no data on treatment effectiveness or follow-ups.<sup>16</sup> The current report complements the hematology literature on anemia and its role in triggering schizophrenia relapse.

## The Case

The patient is a 48-year-old female who was diagnosed with schizophrenia in 2014. Initially, multiple antipsychotics were consolidated due to her severe symptoms, and the regimen has been in place ever since due to the presence of residual symptoms (Table 1). Her residual symptoms have been stable and included auditory hallucinations with intact insight and reality testing. Since the first episode, she has displayed good treatment compliance and never experienced

**Table 1** Timeline of Patient's HIV Infection and Schizophrenia

Time	Medical Conditions	Schizophrenia
Late 2012	Diagnosed with HIV infection. Received lamivudine, stavudine, and efavirenz. CD4+ 72 cells/ul. Prophylactic fluconazole and double strength co-trimoxazole given.	N/A
2013	Asymptomatic, no opportunistic infection. Decreased co-trimoxazole to single strength.	Infrequently had hallucinations and irritability associated with alcohol use. Has yet to receive formal diagnosis or treatment.
2014	Asymptomatic, no opportunistic infection. CD4+ 377 cells/ul. VL 85 copies/mL. Discontinued fluconazole and co-trimoxazole.	Displayed severe delusion and hallucination. Hospitalized. Schizophrenia diagnosed. Treated with 6 mg/day of risperidone, 100 mg/month of haloperidol decanoate, and 50 mg/month of fluphenazine. Became alcohol-abstinent ever since.
2015	Asymptomatic, no opportunistic infection. CD4+ between 575 cells/ul. VL 56 copies/mL.	Residual auditory hallucinations with intact insight. No delusion or disorganized behavior. Functioned stably in housekeeping. Antipsychotic drug regimen unchanged. Good compliance
2016–2019	Asymptomatic, no opportunistic infection. CD4+ 880–1082 cells/ul. VL <40 copies/mL.	Stable
2020	Anti-HIV drugs were changed to lamivudine, zidovudine, and efavirenz due to supply issues. Asymptomatic, no opportunistic infection. CD4+ 1935 cells/ul. VL <20 copies/mL.	Stable
2021 – January 2022	Asymptomatic, no opportunistic infection. CD4+ 1270–1317 cells/ul. VL <20 copies/mL.	Stable
April 2022	Unremarkable. Reportedly compliant to treatment.	Increased irritability. Loss of insight into own condition. Responded to hallucination. Slow thinking and speech. Decreased housekeeping ability. Reported headache, fatigue, and cold intolerance. Reportedly compliant to treatment.
May 2022	Unremarkable. Reportedly compliant to treatment.	Increased headache and fatigue. Visited ER. Dismissed as schizophrenia relapse. No investigation carried out.
June 2022	Combined immunohemolytic and pure-red cell aplastic anemia were found; Hb 4.2 g/dl. Hospitalized. Received 2 units of LPRC; Hb raised to 7.8 g/dl. Zidovudine was implicated and discontinued. Anti-HIV regimen changed to tenofovir, emtricitabine, and efavirenz. Started on 60 mg/day of prednisolone for immunohemolysis.	Visited psychiatric OPD which led to investigations. Psychotic symptoms promptly improved after transfusion. No psychiatric medication changes. Discharged after 2 days.
July 2022	HIV: asymptomatic. No anemic symptoms. Hb was 7.3 g/dl with no signs of ongoing hemolysis. Prednisolone continued at same dose.	Stable (same as 2015–2021 baseline)

(Continued)

**Table 1** (Continued).

Time	Medical Conditions	Schizophrenia
August 2022	HIV: asymptomatic. No anemic symptoms. Hb rose to 10.6 g/dl with no signs of ongoing hemolysis. Prednisolone discontinued.	Stable
September 2022	HIV: asymptomatic. No anemic symptoms.	Stable
December 2022	HIV: asymptomatic. No anemic symptoms. Hb rose to 12.0 g/dl with no signs of ongoing hemolysis. Normal reticulocyte counts.	Stable

**Abbreviations:** CD4+, CD4+ positive cell counts; VL, HIV viral loads; LPRC, leukocyte-poor packed red cell; Hb, hemoglobin level.

relapse. The clinical global impression-severity was 2 (borderline ill) and clinical global impression-improvement was 1 (marked improvement from initial encounter). The patient functioned stably in her housekeeping duties.

Her medical history was significant for HIV infection, which was diagnosed in 2012. Initial CD4+ count at the time of diagnosis was 72 cells/ul, which rose to 377 cells/ul in the first year of treatment with lamivudine, stavudine, and efavirenz. She never had any opportunistic infection. Past self-reported pill counts indicated excellent compliance. Antiretroviral regimen was changed once owing to changes in locally available formulary (Table 1) to lamivudine, zidovudine, and efavirenz in 2020. In the past 3 yearly laboratory investigations, her CD4+ cell counts were between 1163–1935 cells/ul and viral loads were all < 20 copies/mL. She had no other underlying diseases.

The current relapse began 2 months prior. Her daughter noted that the patient started to respond to (the ever present) hallucinations while becoming more irritable, yet displayed slower responses to stimuli; these symptoms did not show any signs of fluctuation, nor were disorientations noted. The patient reported that her hallucinations occurred more frequently, and that she lost the ability to differentiate between hallucinations and reality. She also complained of fatigue, headache, and cold intolerance. Noncompliance was ruled out as the daughter noted that the patient regularly took her medicines and went for monthly injections while remaining pill counts were consistent with follow-up visit date. The patient was brought to the emergency department twice for her somatic complaints. In both instances, two separate physicians focused more on the relapse of psychotic symptoms and only prescribed intramuscular haloperidol without performing laboratory investigation before discharging the patient. The patient later came for a regular psychiatric follow-up visit and reported the relapse and somatic symptoms. The psychiatrist ascertained that there was no compliance issue, nor was there comorbid use of tobacco, alcohol, or illicit substances that could have triggered a psychotic episode or affected pharmacokinetics of the prescribed medication. Examination was positive for systolic ejection murmur. There was no thyroid enlargement, peripheral edema, or abnormalities in lung auscultation. Neurological examination was normal. Investigation revealed a hemoglobin level of 4.7 g/dl with multiple microspherocytes seen in peripheral blood smear; there was no history of hereditary spherocytosis or notes of spherocytes in complete blood counts in the past 10 years. Direct Coomb's test was positive (3+). Reticulocyte count, however, was not elevated (reticulocyte 0.24%, absolute count 3000 cells/ul). Iron studies were normal. Vitamin B12 level was within intermediate range and was deemed unexplanatory of the low reticulocyte count. (The cause of borderline low vitamin B12 was attributed to her self-medication with omeprazole for dyspepsia). Combined autoimmune hemolytic anemia and pure red cell aplasia attributed to zidovudine was provisionally diagnosed. Infectious specialist ruled out possibilities of anemia and psychotic symptoms from HIV, as her infection had been under good control. As her homocysteine level, the marker of abnormality in one-carbon metabolism pathway and the implicated mechanism of psychosis from vitamin B12 deficiency, was within normal range, psychosis from the vitamin status was ruled out. No abnormalities were seen in serum electrolyte panels, thyroid functions, and liver functions, nor was there rhabdomyolysis as evaluated by serum creatine phosphokinase, lactate dehydrogenase and urine myoglobin, ruling out their contribution to psychosis and somatic symptoms.

Transfusion with 2 units of leukocyte-poor packed red blood cells was initiated. After her hemoglobin level rose to 7.8 g/dl over the course of the night the transfusion was carried out, her psychotic symptoms promptly abated: frequency

of hallucination became rare, insight and reality testing returned, and mood and affect became euthymic. The recovery was maintained throughout the admission. No adjustment in psychiatric medication was necessary. As zidovudine was implicated as etiology of anemia, the anti-HIV regimen was changed to tenofovir, emtricitabine, and efavirenz. 60 mg/d of prednisolone was given for immunohemolysis. At 2-week follow-up her hemoglobin level was similar to post-transfusion (7.3 g/dl) without any ongoing signs of hemolysis in blood smear, and schizophrenia symptoms were stable. At 3-months, and 6-months follow-ups, her schizophrenia remained in quiescence and her anemia gradually improved (Table 1). Self-reported compliance and leftover pill counts indicated good compliance.

## Ethical Considerations

This case report was approved by Human Research Ethics Committee of Srinakharinwirot University (number: SWUEC-M-075/2565E). Written informed consent for publication of case details and any accompanying images was obtained from the patient during the period of stable psychiatric symptoms as per the ethics committee's approval. The authors' institution did not require approval to publish case detail.

## Discussion

### Zidovudine and Anemia

Anemia in the present case was attributed to zidovudine. The agent is known to cause anemia from multiple mechanisms, including immunohemolysis and bone marrow suppression. Latency from drug initiation can be years,<sup>17–21</sup> which is consistent with presentation in our case. HIV infection itself has also been associated with development of immunohemolysis but only in severely immunocompromised hosts,<sup>22,23</sup> which is unlikely as the patient's HIV infection had been under good control.

Immunohemolysis was evident from direct Coomb's test and typical peripheral blood smear. Pure red cell aplasia, another anemic condition known to be triggered by zidovudine, was inferred from the lack of reactive reticulocytosis to the 2-month course of anemia despite the absence of nutritional deficiency. The absence of bone marrow study results in this case, however, precluded a firm diagnosis of the latter condition.

### Different Causes of Anemia and Psychosis

Reports on psychosis from anemia are still sparse. Most were related to megaloblastic anemia associated with vitamin B12 and folate deficiency ("megaloblastic madness").<sup>24</sup> Historic cases reported that psychoses in pernicious anemia were treatable with electroconvulsion.<sup>25,26</sup> The response to the same treatment as schizophrenia spectrum psychoses may imply shared pathological processes. More recently, a report described a case with megaloblastic anemia presenting as subacute disorganized behaviors and memory impairment. The case improved after three days of vitamin B12 administration.<sup>27</sup> Normalization of hematopoiesis could not have occurred in such short period. This is also consistent with other reports in which psychoses occurred in isolated vitamin B12 deficiency without megaloblastic anemia,<sup>28–30</sup> pointing to the deficiency's independent effect such as homocysteinemia due to problems in one-carbon metabolisms or abnormalities in synthesis of neurotransmitters.<sup>10,11,31</sup> Similarly, the widely studied iron deficiency anemia is also implicated as the predisposing factor of schizophrenia,<sup>32–34</sup> but the mechanism driving development of psychosis appears to be from iron status deviating brain developmental trajectories.<sup>13,35–37</sup> Therefore, psychoses from these two entities likely followed mechanisms different from that of the present case.

There is a report of a case with exacerbated chronic familial hemolytic anemia (hemoglobin 3.7 g/dl) following *Clostridium perfringens* sepsis which caused psychosis. In contrast to our case, this patient developed paranoid psychosis, aggression, and disorientation after transfusion, and only improved with subsequent antibiotics treatment.<sup>38</sup> The clinical picture is likely that of delirium (as opposed to our case), which can be attributed to either anemia, sequelae of hemolysis, transfusion reaction, and/or sepsis.

A similar clinical situation was reported in a stable schizophrenia patient who developed combined megaloblastic and autoimmune hemolytic anemia. Despite having similarly low hemoglobin level (initially 6.5 g/dl, later dropped to 5.4 g/dl), this patient did not experience relapse of psychotic symptoms as reported in the present case despite having

hemoglobin level only slightly higher than our case.<sup>39</sup> The report stated that the patient's psychosis was in remission, a different baseline from our case whose residual symptoms had been present. The residual symptoms point to a more severe pathology that required greater compensatory functions and, possibly, a greater vulnerability to any loss.

## Anemia, Cognitive Functions, and the Link with Psychological Insight

The mechanism by which anemia induced psychosis in the present case was possibly different from those in micronutrient deficiency or sepsis. The possibility that autoimmunity status mediated the exacerbation is also unlikely, as the psychosis resolved prior to initiation of prednisolone. We hypothesize the mechanism of impairment and recovery of cognitive function explaining the relapse and prompt recovery with transfusion. As previously noted, the patient's insight and reality testing only became impaired during this episode. In modern sense, the psychoanalytic-inclined term of reality testing and insight has now been viewed as an expression of cognitive functions.<sup>40–42</sup> Recent views on schizophrenia have implicated the decline in cognitive functions as one of the triggers of conversion from high-risk states (including attenuated psychosis syndrome and brief limited intermittent psychotic symptoms) to schizophrenia.<sup>43</sup> If so, a decline in sensitive cognitive functions in a patient with established disease should also be able to trigger a schizophrenia relapse. In this case, the role of anemia was apparent. Anemia disrupts the oxygenation of the central nervous system, impairing cognitive functions. Two experiments examined reaction time and memory in iatrogenically-produced acute normovolemic anemia. These cognitive functions started to decline subtly at hemoglobin level of 6 g/dl (approximately 8 g/dl below mean pre-dilution concentration). Autotransfusion reversed the impairment, while administration of supplemental oxygen alone could also create partial improvement.<sup>44,45</sup> This suggests that poor oxygenation contributed to the deficits. A further experiment found that the impaired cognitive functions were attributable to impaired central processing.<sup>46</sup> Although these studies have yet to explore the anemia's and transfusion's effects on other cognitive domains, it can be presumed that deficits and recoveries occur simultaneously. Unfortunately, these studies explored changes in cognition in short-term anemia. The present case's anemia had likely developed over the past two months and whether the experiment's findings are generalizable is not known. Chronic anemia can be followed by compensation and decompensation processes which can distort its effects on cognitive functions related to psychological insight. Nevertheless, data from commonly encountered chronic anemia such as iron deficiency, end-stage renal disease, sickle cell anemia, and thalassemia seem to indicate the presence of cognitive disturbances in these entities as well, although their disease-specific pathophysiology may also be operating on top of anemia itself.<sup>47–51</sup> Chronic anemia in the elderly and oncologic patients has also been associated with reversible cognitive deficits.<sup>52,53</sup>

## The Present Case and Implications

From the psychiatric perspective, a disease relapse is a function of risk factors. For schizophrenia, common risk factors are medication discontinuation and substance use, which were not present in this case. Another strong factor is the disease's chronicity, which is assumed to be accompanied by ongoing pathological processes such as low-grade systemic inflammation and brain function deterioration.<sup>54–59</sup> Moreover, the chronic use of antipsychotics and the patient's sedentary lifestyle could have led to metabolic derangements, potentially worsening the inflammatory condition.<sup>60</sup> Her HIV infection, although well controlled, can also exert subtle inflammatory disturbances that chronically deteriorate brain function and adds to the predisposition.<sup>61</sup> These factors are then precipitated into a syndromic relapse by the emergence of severe anemia.

From her course of physical symptoms and relatively preserved level of consciousness, it was suspected that her anemia may have been gradually progressing over the past two months, concurrent with the re-emergence of psychotic symptoms. Due to the absence of symptom fluctuation and disorientation, the psychosis was unlikely a part of delirium. Therefore, the re-emergence of symptoms was diagnosed as schizophrenia relapse. Her reality testing, insight, and auditory hallucination recovered to baseline after transfusion raising hemoglobin level from 4.2 to 7.8 g/dl. The rapid improvement of insight could be a product of recovery of sensitive cognitive functions, similar to situations observed in iatrogenic normovolemic anemia experiments. Hallucination has been postulated as a disorder of brain regions generating inner speech, while the insight or the ability to tell hallucination apart from reality is an amalgam of self-certainty, self-reflection, executive functions, and memories.<sup>62</sup> Apparently, the scope far exceeds those studied in iatrogenic anemia;

what we can assume from the phenomenon in this case is that said cognitive functions (and responsible brain regions) are sensitive to hypoxemia. Nevertheless, ascertaining whether schizophrenia relapses can occur from transient cognitive decline from anemia requires further studies. Moreover, whether the brain's reactive or autoregulatory changes toward anemia (vascular, metabolic, hormonal, etc) contribute to risk or protection of relapses also requires further studies.

There is also a paucity of reports of anemia triggering relapse in cases of established psychiatric illnesses other than schizophrenia. Generalizing about this suggested mechanism of impaired cognitive function, clinicians encountering anemia may also look for emergence or relapse of other psychiatric diseases in which cognitive dysfunctions play substantial roles, such as depression, anxiety, and neurocognitive disorders.<sup>63–68</sup> These conditions involve different cognitive domains as opposed to schizophrenia which may become impaired at a different severity of anemia.

For clinicians encountering relapses of schizophrenia or mood disorders, consideration should be given that anemia could be among the differential diagnoses. When occurring in concert with anemia, correction of anemia alone may resolve these psychiatric symptoms. Psychotropic medication adjustment may be unnecessary or only used judiciously for temporary stabilization of severe agitation. For psychiatrists, monitoring for signs of anemia, surveillance of blood counts when indicated, and prompt referral for hematological treatment will serve to complement biological aspects of psychiatric care.

## Limitations

There were limitations in the definite diagnosis of anemia in the present case. The onset was presumed from somatic symptom history. The comorbid diagnosis of pure red cell aplasia was presumptive and lacked bone marrow study data. Although much rarer than zidovudine-induced one, HIV-related immunohemolysis in well controlled cases remained a possibility. The possible underlying HIV infection-associated brain pathology and subsequent predisposition toward triggers of decompensation might differentiate the case from typical schizophrenia patients.

## Conclusion

A case of a stable schizophrenia patient who experienced relapse following severe anemia from zidovudine-related immunohemolysis and red cell aplasia was described. Schizophrenia symptoms promptly returned to baseline following transfusion and did not necessitate changes in psychiatric medication; symptoms remained stable over 6 months of follow-ups. Clinicians encountering schizophrenia relapses may also evaluate their patients for anemia; such psychoses may be promptly reversible as reported in this case.

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Vieth JT, Lane DR. Anemia. *Hematol Oncol Clin North Am.* 2017;31(6):1045–1060. doi:10.1016/j.hoc.2017.08.008
2. Beghé C, Wilson A, Ershler WB. Prevalence and outcomes of anemia in geriatrics: a systematic review of the literature. *Am J Med.* 2004;116(Suppl 7A):3S–10S. doi:10.1016/j.amjmed.2003.12.009
3. Lucca U, Tettamanti M, Mosconi P, et al. Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the “Health and Anemia” study. *PLoS One.* 2008;3(4):e1920. doi:10.1371/journal.pone.0001920
4. Agrawal S, Kumar S, Ingole V, et al. Does anemia affects cognitive functions in neurologically intact adult patients: two year cross sectional study at rural tertiary care hospital. *J Fam Med Prim Care.* 2019;8(9):3005–3008. doi:10.4103/jfmpc.jfmpc\_599\_19
5. Nazari M, Mohammadnejad E, Dalvand S, Ghanei Gheslagh R. Prevalence of iron deficiency anemia in Iranian children under 6 years of age: a systematic review and meta-analysis. *J Blood Med.* 2019;10:111–117. doi:10.2147/JBM.S196102
6. Kang SY, Kim HB, Sunwoo S. Association between anemia and maternal depression: a systematic review and meta-analysis. *J Psychiatr Res.* 2020;122:88–96. doi:10.1016/j.jpsychires.2020.01.001
7. Hector M, Burton JR. What are the psychiatric manifestations of vitamin B12 deficiency? *J Am Geriatr Soc.* 1988;36(12):1105–1112. doi:10.1111/j.1532-5415.1988.tb04397.x
8. Lachner C, Steinle NI, Regenold WT. The neuropsychiatry of vitamin B12 deficiency in elderly patients. *J Neuropsychiatry Clin Neurosci.* 2012;24(1):5–15. doi:10.1176/appi.neuropsych.11020052
9. Huemer M, Baumgartner MR. The clinical presentation of cobalamin-related disorders: from acquired deficiencies to inborn errors of absorption and intracellular pathways. *J Inherit Metab Dis.* 2019;42(4):686–705. doi:10.1002/jimd.12012
10. Hutto BR. Folate and cobalamin in psychiatric illness. *Compr Psychiatry.* 1997;38(6):305–314. doi:10.1016/S0010-440X(97)90925-1

11. Kale A, Naphade N, Sapkale S, et al. Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. *Psychiatry Res.* 2010;175(1–2):47–53. doi:10.1016/j.psychres.2009.01.013
12. Wiser M, Levkowitz Y, Neuman M, Yehuda S. Decrease of serum iron in acutely psychotic schizophrenic patients. *Int J Neurosci.* 1994;78(1–2):49–52. doi:10.3109/00207459408986045
13. Shah HE, Bhawnani N, Ethirajulu A, et al. Iron deficiency-induced changes in the hippocampus, corpus striatum, and monoamines levels that lead to anxiety, depression, sleep disorders, and psychotic disorders. *Cureus.* 2021. doi:10.7759/cureus.18138
14. Sadock BJ, Sadock VA, Ruiz P. *Kaplan & Sadock's Comprehensive Textbook of Psychiatry*. Tenth ed. Wolters Kluwer; 2017.
15. Wysokiński A, Szczepocka E. Red blood cells parameters in patients with acute schizophrenia, unipolar depression and bipolar disorder. *Psychiatr Danub.* 2018;30(3):323–330. doi:10.24869/psyd.2018.323
16. Dudley AW, Waddell CC. Crisis in sickle cell trait. *Hum Pathol.* 1991;22(6):616–618. doi:10.1016/0046-8177(91)90242-H
17. Telen MJ, Roberts KB, Bartlett JA. HIV-associated autoimmune hemolytic anemia: report of a case and review of the literature. *J Acquir Immune Defic Syndr.* 1990;3(10):933–937.
18. Barry M, Howe JL, Back DJ, et al. Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. *Br J Clin Pharmacol.* 1994;37(1):7–12. doi:10.1111/j.1365-2125.1994.tb04231.x
19. Koduri PR, Singa P, Nikolinakos P. Autoimmune hemolytic anemia in patients infected with human immunodeficiency virus-1. *Am J Hematol.* 2002;70(2):174–176. doi:10.1002/ajh.10096
20. Balakrishnan A, Valsalan R, Sheshadri S, Pandit VR, Medep V, Agrawal RK. Zidovudine-induced reversible pure red cell aplasia. *Indian J Pharmacol.* 2010;42(3):189–191. doi:10.4103/0253-7613.66845
21. Insiripong S. HIV infection complicated by autoimmune hemolytic anemia (AIHA): a case report. *J Hematol Transfus Med.* 2017;27:159–163.
22. Iordache L, Launay O, Bouchaud O, et al. Autoimmune diseases in HIV-infected patients: 52 cases and literature review. *Autoimmun Rev.* 2014;13(8):850–857. doi:10.1016/j.autrev.2014.04.005
23. Kebede SS, Yalew A, Yesuf T, Melku M, Bambo GM, Woldu B. The magnitude and associated factors of immune hemolytic anemia among human immunodeficiency virus infected adults attending University of Gondar comprehensive specialized hospital north west Ethiopia 2021 GC, cross sectional study design. *PLoS One.* 2022;17(10):e0274464. doi:10.1371/journal.pone.0274464
24. Dogan M, Ozdemir O, Sal EA, et al. Psychotic disorder and extrapyramidal symptoms associated with vitamin B12 and folate deficiency. *J Trop Pediatr.* 2009;55(3):205–207. doi:10.1093/tropej/fmn112
25. Ende M, Klauber B, Gendel BR. Electric shock therapy of acute psychosis associated with pernicious anemia; report of a case. *Arch Neurol Psychiatry.* 1950;63(1):110–112. doi:10.1001/archneuro.1950.02310190116009
26. Betts WC. The use of electroshock therapy in a psychosis associated with pernicious anemia. *N C Med J.* 1952;13(7):321–324.
27. Tripathi AK, Verma SP, Himanshu D. Acute psychosis: a presentation of cyanocobalamin deficiency megaloblastic anemia. *Indian J Hematol Blood Transfus.* 2010;26(3):99–100. doi:10.1007/s12288-010-0032-4
28. Payinda G, Hansen T. Vitamin B(12) deficiency manifested as psychosis without anemia. *Am J Psychiatry.* 2000;157(4):660–661. doi:10.1176/appi.ajp.157.4.660
29. Masalha R, Chudakov B, Morad M, Rudoy I, Volkov I, Wirguin I. Cobalamin-responsive psychosis as the sole manifestation of vitamin B12 deficiency. *Isr Med Assoc J.* 2001;3(9):701–703.
30. Silva B, Velosa A, Barahona-Corrêa JB. Reversible dementia, psychotic symptoms and epilepsy in a patient with vitamin B12 deficiency. *BMJ Case Rep.* 2019;12(5):e229044. doi:10.1136/bcr-2018-229044
31. Green R, Miller JW. Vitamin B12 deficiency. In: *Vitamins and Hormones*. Vol. 119. Elsevier; 2022:405–439.
32. Insel BJ, Schaefer CA, McKeague IW, Susser ES, Brown AS. Maternal iron deficiency and the risk of schizophrenia in offspring. *Arch Gen Psychiatry.* 2008;65(10):1136–1144. doi:10.1001/archpsyc.65.10.1136
33. Sørensen HJ, Nielsen PR, Pedersen CB, Mortensen PB. Association between prepartum maternal iron deficiency and offspring risk of schizophrenia: population-based cohort study with linkage of Danish national registers. *Schizophr Bull.* 2011;37(5):982–987. doi:10.1093/schbul/sbp167
34. Maxwell AM, Rao RB. Perinatal iron deficiency as an early risk factor for schizophrenia. *Nutr Neurosci.* 2022;25(10):2218–2227. doi:10.1080/1028415X.2021.1943996
35. Pisansky MT, Wickham RJ, Su J, et al. Iron deficiency with or without anemia impairs prepulse inhibition of the startle reflex: iron deficiency impairs prepulse inhibition. *Hippocampus.* 2013;23(10):952–962. doi:10.1002/hipo.22151
36. Kim SW, Stewart R, Park WY, et al. Latent iron deficiency as a marker of negative symptoms in patients with first-episode schizophrenia spectrum disorder. *Nutrients.* 2018;10(11):1707. doi:10.3390/nu10111707
37. Sui YV, McKenna F, Bertisch H, et al. Decreased basal ganglia and thalamic iron in early psychotic spectrum disorders are associated with increased psychotic and schizotypal symptoms. *Mol Psychiatry.* 2022;27(12):5144–5153. doi:10.1038/s41380-022-01740-2
38. Egyed M, Rajnic P, Kollár B, Sinkó J, Zsoldos E, Repa I. Severe hemolytic anemia and acute psychosis caused by *Clostridium perfringens* sepsis. *Med Sci Monit.* 2008;14(3):CS13–16.
39. Vucelić V, Stancić V, Ledinsky M, et al. Combined megaloblastic and immunohemolytic anemia associated--a case report. *Acta Clin Croat.* 2008;47(4):239–243.
40. Bentall RP, Slade PD. Reality testing and auditory hallucinations: a signal detection analysis. *Br J Clin Psychol.* 1985;24(3):159–169. doi:10.1111/j.2044-8260.1985.tb01331.x
41. McDannald M, Schoenbaum G. Toward a model of impaired reality testing in rats. *Schizophr Bull.* 2009;35(4):664–667. doi:10.1093/schbul/sbp050
42. McDannald MA, Whitt JP, Calhoun GG, et al. Impaired reality testing in an animal model of schizophrenia. *Biol Psychiatry.* 2011;70(12):1122–1126. doi:10.1016/j.biopsych.2011.06.014
43. Cannon TD. How schizophrenia develops: cognitive and brain mechanisms underlying onset of psychosis. *Trends Cogn Sci.* 2015;19(12):744–756. doi:10.1016/j.tics.2015.09.009
44. Weiskopf RB, Kramer JH, Viele M, et al. Acute severe isovolemic anemia impairs cognitive function and memory in humans. *Anesthesiology.* 2000;92(6):1646–1652. doi:10.1097/0000542-200006000-00023
45. Weiskopf RB, Feiner J, Hopf HW, et al. Oxygen reverses deficits of cognitive function and memory and increased heart rate induced by acute severe isovolemic anemia. *Anesthesiology.* 2002;96(4):871–877. doi:10.1097/0000542-200204000-00014

46. Weiskopf RB, Toy P, Hopf HW, et al. Acute isovolemic anemia impairs central processing as determined by P300 latency. *Clin Neurophysiol.* 2005;116(5):1028–1032. doi:10.1016/j.clinph.2004.12.009
47. Allali S, Brousse V, Sacri AS, Chalumeau M, de Montalembert M. Anemia in children: prevalence, causes, diagnostic work-up, and long-term consequences. *Expert Rev Hematol.* 2017;10(11):1023–1028. doi:10.1080/17474086.2017.1354696
48. Choi S, O'Neil SH, Joshi AA, et al. Anemia predicts lower white matter volume and cognitive performance in sickle and non-sickle cell anemia syndrome. *Am J Hematol.* 2019;94(10):1055–1065. doi:10.1002/ajh.25570
49. Drew DA, Weiner DE, Sarnak MJ. Cognitive impairment in CKD: pathophysiology, management, and prevention. *Am J Kidney Dis.* 2019;74(6):782–790. doi:10.1053/j.ajkd.2019.05.017
50. Prussien KV, Compas BE, Siciliano RE, et al. Cerebral hemodynamics and executive function in sickle cell anemia. *Stroke.* 2021;52(5):1830–1834. doi:10.1161/STROKEAHA.120.032741
51. Limpawattana P, Juntararungtong T, Teawtrakul N, et al. Cognitive impairment in thalassemia and associated factors. *Dement Geriatr Cogn Disord.* 2022;51(2):128–134. doi:10.1159/000522655
52. Cunningham RS. Anemia in the oncology patient: cognitive function and cancer. *Cancer Nurs.* 2003;26:38S??42S. doi:10.1097/00002820-200312001-00009
53. Kung WM, Yuan SP, Lin MS, et al. Anemia and the risk of cognitive impairment: an updated systematic review and meta-analysis. *Brain Sci.* 2021;11(6):777. doi:10.3390/brainsci11060777
54. Adomaitienė V, Jaras A, Lauciūtė E, Liugailaitė S, Dambrauskienė K. P03-16 - causes and first symptoms of schizophrenia relapse. *Eur psychiatr.* 2010;25(S1):1.
55. Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. *BMC Psychiatry.* 2013;13(1):50. doi:10.1186/1471-244X-13-50
56. Momtazmanesh S, Zare-Shahabadi A, Rezaei N. Cytokine alterations in schizophrenia: an updated review. *Front Psychiatry.* 2019;10:892. doi:10.3389/fpsy.2019.00892
57. Pothimas N, Tungpunkom P, Chanprasit C, Kitsumban V, Cross-sectional A. Study of factors predicting relapse in people with schizophrenia. *PRIJNR.* 2020;24(4):448–459.
58. Fond G, Lançon C, Korchia T, Auquier P, Boyer L. The role of inflammation in the treatment of schizophrenia. *Front Psychiatry.* 2020;11:160. doi:10.3389/fpsy.2020.00160
59. Sahpolat M, Ayar D, Ari M, Karaman MA. Elevated monocyte to high-density lipoprotein ratios as an inflammation markers for schizophrenia patients. *Clin Psychopharmacol Neurosci.* 2021;19(1):112–116. doi:10.9758/cpn.2021.19.1.112
60. Parksepp M, Haring L, Kilk K, et al. A marked low-grade inflammation and a significant deterioration in metabolic status in first-episode schizophrenia: a five-year follow-up study. *Metabolites.* 2022;12(10):983. doi:10.3390/metabo12100983
61. Portilla I, Reus S, León R, et al. Neurocognitive impairment in well-controlled HIV-infected patients: a cross-sectional study. *AIDS Res Hum Retroviruses.* 2019;35(7):634–641. doi:10.1089/aid.2018.0279
62. Ohmuro N, Katsura M, Obara C, et al. The relationship between cognitive insight and cognitive performance among individuals with at-risk mental state for developing psychosis. *Schizophr Res.* 2018;192:281–286. doi:10.1016/j.schres.2017.04.031
63. Daleiden E. An information-processing perspective on childhood anxiety. *Clin Psychol Rev.* 1997;17(4):407–429. doi:10.1016/S0272-7358(97)00010-X
64. Castaneda AE, Tuulio-Henriksson A, Marttunen M, Suvisaari J, Lönnqvist J. A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults. *J Affect Disord.* 2008;106(1–2):1–27. doi:10.1016/j.jad.2007.06.006
65. Murrrough JW, Iacoviello B, Neumeister A, Charney DS, Iosifescu DV. Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies. *Neurobiol Learn Mem.* 2011;96(4):553–563. doi:10.1016/j.nlm.2011.06.006
66. Carvalho A, Miskowiak K, Hyphantis T, et al. Cognitive dysfunction in depression – pathophysiology and novel targets. *CNSNDT.* 2015;13(10):1819–1835. doi:10.2174/1871527313666141130203627
67. Hur J, Stockbridge MD, Fox AS, Shackman AJ. Dispositional negativity, cognition, and anxiety disorders: an integrative translational neuroscience framework. In: *Progress in Brain Research.* Vol. 247. Elsevier; 2019:375–436.
68. Shi R, Sharpe L, Abbott M. A meta-analysis of the relationship between anxiety and attentional control. *Clin Psychol Rev.* 2019;72:101754. doi:10.1016/j.cpr.2019.101754

Journal of Blood Medicine

Dovepress

## Publish your work in this journal

The Journal of Blood Medicine is an international, peer-reviewed, open access, online journal publishing laboratory, experimental and clinical aspects of all aspect pertaining to blood based medicine including but not limited to: Transfusion Medicine; Blood collection, Donor issues, Transmittable diseases, and Blood banking logistics; Immunohematology; Artificial and alternative blood based therapeutics; Hematology; Biotechnology/nanotechnology of blood related medicine; Legal aspects of blood medicine; Historical perspectives. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/journal-of-blood-medicine-journal>